Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine tartrate 0.5% gel for severe facial erythema of rosacea
NCT01885000Phase 3Completed
- Sponsor
- Galderma
- Start
- Jul 2013
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in rosacea comparing Brimonidine tartrate 0.5% gel with Vehicle (2 arms). Primary endpoints: Percentage of Participants Who Are Very Satisfied/Satisfied/Somewhat Satisfied With the Overall Study Treatment at 8 days, Percentage of Participants With Facial Redness Questionnaire at 8 days and 3 more. Started Jul 2013; status: completed.
02
Drugs
Onreltea
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT01885000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01885000.